IMMUNOCYTOCHEMICAL/MOLECULAR PATHOLOGY TECHNIQUES APPLIED TO CYTOPATHOLOGY

“去年停产，是我工作的重点 已经对几种免疫细胞化学进行了重点分析 细胞学领域，以及分子技术的应用 到细胞病理学。我一直在评估一个新的 MART1抗体在转移性恶性肿瘤中的表达 黑色素瘤，其结果影响免疫治疗。其他 涉及MART1的项目包括：形态和 渗出液中黑色素瘤细胞的免疫细胞化学分析 老年人正常器官尸检资料与肿瘤的研究进展 恶性黑色素瘤的鉴别诊断对MART1的评估 非黑色素瘤HMB45阳性表达的回顾 肿瘤MART1染色的比较；MART-1染色的比较 目的：探讨恶性黑色素瘤FNA材料中HMB45的表达。 这些研究对于描述这一新的 抗体。我曾参与使用显微解剖和聚合酶链式反应 用于检测原代和FNAs中的特异性等位基因丢失 转移性肾细胞癌，以证明在有 已知的基因改变这些技术可以用于 转移性病变的阳性鉴别 原发肿瘤和正常组织。我们也在使用这些 在选择的细胞学样本中使用困难的细胞的技术 通过使用形态学和 免疫细胞化学，看看恶性肿瘤是否有明确的诊断 可以通过对不同细胞群体的聚合酶链式反应进行分析 与原发肿瘤相比。最近，我有 开始了一个项目，再次使用显微解剖和聚合酶链式反应，在 黑色素瘤FNAS对P16基因杂合性缺失的评估 PCR分析所需的细胞计数。最近，我们 已应用显微解剖和聚合酶链式反应检测杂合性缺失 良性和恶性肾上腺组织/肿瘤的FNA， 希望利用对特定基因异常的分析来诊断 肾上腺病变的FNA诊断研究：P53、1p和 VHL基因。“

"Discontinued In the last year, the focus of my work has been on the immunocytochemical analyses of several focused areas of cytology, as well as the application of molecular techniques to cytopathology. I have been evaluating the expression of a new antibody, MART1, for it's expression in metastatic malignant melanoma, the results of which impacts on immunotherapy. Other projects involving MART1 include: the morphologic and immunocytochemical analysis of melanoma cells in effusions; a review of normal organ autopsy material and neoplasms in the differential diagnosis of malignant melanoma to evaluate MART1 expression; a review of non-melanomatous HMB45 positive neoplasms to compare MART1 staining; a comparision of MART-1 to HMB45 expression in FNA material of Malignant melanomas. These studies are important for the characterizations of this new antibody. I have been involved in using microdissection and PCR for the detection of specific allelic loss in primary and FNAs of metastatic renal cell carcinomas, to prove that in tumors with known genetic alterations these techniques can be used for the positive identification of metastatic lesions by comparison with the primary neoplasm and normal tissue. We are also using these techniques in selected cytologic samples with cells that are difficult to identify positively through the use of morphology and immunocytochemistry, to see if a definitive diagnosis of malignancy can be made through the PCR analysis of different cell populations with comparison to the primary neoplasm. Most recently, I have begun a project, again employing microdissection and PCR, in FNAs of melanoma for the evaluation of LOH for P16 as well as enumeration of cells required forPCR analysis.Most recently we have applied microdissection and PCR for the detection of LOH in FNAs of benign and malignant adrenal tissue/neoplasms, in the hopes of utilizing analyses of specific genetic abnormalities for the diagnosis of adrenal lesions on FNA.Loci studied wer p53, 1p and the VHL gene."